Hilal Tekatli

Organs at risk proximity in central lung stereotactic ablative radiotherapy: A comparison of four-dimensional computed tomography and magnetic resonance-guided breath-hold delivery techniques.

Journal: Physics and imaging in radiation oncology

Published: November 27, 2024

Artificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 01, 2024

Ten years outcomes after SABR in central and ultracentral primary lung tumors.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: April 12, 2023

Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: March 28, 2023

The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: May 08, 2020

Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 23, 2018

Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.

Journal: International journal of radiation oncology, biology, physics

Published: March 07, 2018

Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling.

Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Published: October 30, 2017

Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors.

Journal: International journal of radiation oncology, biology, physics

Published: May 05, 2017

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 08, 2016

Organs at risk proximity in central lung stereotactic ablative radiotherapy: A comparison of four-dimensional computed tomography and magnetic resonance-guided breath-hold delivery techniques.

Organs at risk proximity in central lung stereotactic ablative radiotherapy: A comparison of four-dimensional computed tomography and magnetic resonance-guided breath-hold delivery techniques.

Artificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors.

Artificial intelligence-assisted quantitative CT analysis of airway changes following SABR for central lung tumors.

Ten years outcomes after SABR in central and ultracentral primary lung tumors.

Ten years outcomes after SABR in central and ultracentral primary lung tumors.

Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.

Local control and toxicity after magnetic resonance imaging (MR)-guided single fraction lung stereotactic ablative radiotherapy.

The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.

The development and external validation of an overall survival nomogram in medically inoperable centrally located early-stage non-small cell lung carcinoma.

Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches.

Stereotactic ablative radiotherapy (SABR) for early-stage central lung tumors: New insights and approaches.

Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.

Knowledge-Based Planning for Identifying High-Risk Stereotactic Ablative Radiation Therapy Treatment Plans for Lung Tumors Larger Than 5 cm.

Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling.

Esophagus toxicity after stereotactic and hypofractionated radiotherapy for central lung tumors: Normal tissue complication probability modeling.

Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors.

Normal Tissue Complication Probability Modeling of Pulmonary Toxicity After Stereotactic and Hypofractionated Radiation Therapy for Central Lung Tumors.

Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy.

Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy.

Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.

Use of Stereotactic Ablative Radiotherapy (SABR) in Non-Small Cell Lung Cancer Measuring More Than 5 cm.

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.

Outcomes of Hypofractionated High-Dose Radiotherapy in Poor-Risk Patients with "Ultracentral" Non-Small Cell Lung Cancer.